Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

64.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,311
Open 64.76
Bid (Size) 76.50 (2)
Ask (Size) 78.00 (1)
Prev. Close 64.76
Today's Range 64.76 - 64.76
52wk Range 45.50 - 76.11
Shares Outstanding 94,324,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Via Benzinga

Performance

YTD
-8.13%
-8.13%
1 Month
-0.93%
-0.93%
3 Month
-4.02%
-4.02%
6 Month
+17.79%
+17.79%
1 Year
+2.50%
+2.50%

More News

Read More
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Expert Ratings for Intra-Cellular Therapies
Via Benzinga
Intra-Cellular Therapies's Earnings: A Preview
Via Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Are These Biotechs Ready To Launch?
Via Talk Markets
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
Via Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
Via Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
Via Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for Intra-Cellular Therapies
Via Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
Via Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.